GeneShot

For decades, cancer vaccines were the field's most stubborn disappointment. Tumours mutate too fast, hide too well, and look too much like the body's own cells for the immune system to reliably attack them. That equation is changing.

The treatment, known clinically as mRNA-4157, begins with a biopsy. Researchers sequence the tumour, identify up to 34 of its unique mutations, and within weeks manufacture a custom mRNA vaccine — a personalised set of instructions training the patient's immune system to recognise their cancer and only their cancer.

Vaccine-induced immune responses persisting for nearly four years after treatment in some patients.

In a Phase 2b melanoma trial, patients who received the vaccine alongside Merck's checkpoint inhibitor Keytruda saw their risk of recurrence cut by nearly half compared to Keytruda alone. Phase 3 trials are now underway in melanoma, lung, and pancreatic cancer — three of the diseases where new tools are most urgently needed.

Almost every drug we know works the same way: you take it, it acts, it leaves the body, and you take it again. Gene editing breaks that loop. You are not adding something to the body — you are rewriting a single line of code, once.

The trial in question, run by CRISPR Therapeutics, targeted PCSK9, the gene that regulates how aggressively the liver clears LDL cholesterol from the blood. After one infusion of CTX310, average LDL fell by more than half across the cohort. Two months in, levels had not crept back up.

CRISPR clinical trials have entered a new stage — no longer only proof-of-concept studies.

The first CRISPR therapy, Casgevy, has already been approved for sickle cell disease and beta thalassemia — once-fatal conditions that, for some patients, are now functionally cured. What is shifting now is scope. Trials underway target high cholesterol, hereditary blindness, certain cancers, and rare metabolic disorders that have no other path to treatment.

The science traces back to 2006, when Shinya Yamanaka discovered that just four genes — now called the Yamanaka factors — could reset an adult cell to an embryonic-like state. The implication was extraordinary: ageing, at the cellular level, might be reversible. The catch was that fully reset cells lose their identity and can form tumours.

What followed was twenty years of careful work to apply the factors partially — long enough to roll back the clock, short enough to keep the cell doing its job. Life Biosciences is now bringing that work into people, beginning with optic-nerve diseases where vision loss is irreversible by every existing standard of care.

The FDA has been notably open and forward-thinking in how it engages with this approach.

The first trial targets NAION, a sudden form of optic-nerve damage with no approved treatment. If the therapy can restore even partial function to neurons that have been written off as permanently lost, the implications for neurodegenerative disease — Parkinson's, ALS, age-related blindness — are difficult to overstate.